EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische ÜbersichtOpen Access · CC0

Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis

Yau Adamu iD, Mireia Puig-Asensio, Bashir Dabo, Marin L Schweizer iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0293423 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Yau Adamu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Bayero University, Kano, Nigeria. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Daptomycin, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs), vancomycin stands as the prevalent therapeutic agent. Daptomycin remains an alternative antibiotic to treat MRSA BSIs in cases where vancomycin proves ineffective. However, studies have conflicted on whether daptomycin is more effective than vancomycin among patients with MRSA BSI.

Objective

To compare the effectiveness of daptomycin and vancomycin for the prevention of mortality among adult patients with MRSA BSI.

Methods

Systematic searches of databases were performed, including Embase, PubMed, Web of Science, and Cochrane Library. The Newcastle Ottawa Scale (NOS) and Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) were used to assess the quality of individual observational and randomized control studies, respectively. Pooled odd ratios were calculated using random effects models.

Results

Twenty studies were included based on a priori set inclusion and exclusion criteria. Daptomycin treatment was associated with non-significant lower mortality odds, compared to vancomycin treatment (OR = 0.81; 95% CI, 0.62, 1.06). Sub-analyses based on the time patients were switched from another anti-MRSA treatment to daptomycin demonstrated that switching to daptomycin within 3 or 5 days was significantly associated with 55% and 45% decreased odds of all-cause mortality, respectively. However, switching to daptomycin any time after five days of treatment was not significantly associated with lower odds of mortality. Stratified analysis based on vancomycin minimum inhibitory concentration (MIC) revealed that daptomycin treatment among patients infected with MRSA strains with MIC≥1 mg/L was significantly associated with 40% lower odds of mortality compared to vancomycin treatment.

Conclusion

Compared with vancomycin, an early switch from vancomycin to daptomycin was significantly associated with lower odds of mortality. In contrast, switching to daptomycin at any time only showed a trend towards reduced mortality, with a non-significant association. Therefore, the efficacy of early daptomycin use over vancomycin against mortality among MRSA BSIs patients may add evidence to the existing literature in support of switching to daptomycin early over remaining on vancomycin. More randomized and prospective studies are needed to assess this association.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDaptomycinMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsVancomycinHumansBacteremiaTreatment Outcome

Substanzen

Anti-Bacterial AgentsDaptomycinVancomycin

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Bayero University, Kano, Nigeria.
  • Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America.
  • College of Public Health, University of South Florida, Tampa, Florida, United States of America.
  • Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States of America.

ORCID-Profile: Yau Adamu, Marin L Schweizer

Zitieren

APA

Adamu, Y., Puig-Asensio, M., Dabo, B., & Schweizer, M. L. (2024). Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0293423

Vancouver

Adamu Y, Puig-Asensio M, Dabo B, Schweizer ML. Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis. PLOS ONE. 2024. doi:10.1371/journal.pone.0293423

BibTeX
@article{Adamu2024,
  author = {Adamu, Yau and Puig-Asensio, Mireia and Dabo, Bashir and Schweizer, Marin L},
  title = {Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0293423}
}
Kostenlos starten →